STUART; Darrin

Patent Applications and Registrations

Patent applications and USPTO patent grants for STUART; Darrin.The latest application filed is for "therapeutic combinations comprising a c-raf inhibitor".

Company Profile

4.13.20

STUART; Darrin - Marblehead MA
Stuart; Darrin - Pleasant Hill CA
Stuart; Darrin - Emeryville CA
Stuart; Darrin - Concord CA
Stuart; Darrin - Pleasent Hill CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Therapeutic Combinations Comprising A C-raf Inhibitor App 20220008426 - CAPONIGRO; Giordano ; et al.	2022-01-13
Method of treating a proliferative disease Grant 11,007,194 - Stuart , et al. May 18, 2	2021-05-18
Therapeutic uses of a C-RAF inhibitor Grant 10,973,829 - Caponigro , et al. April 13, 2	2021-04-13
Combination Therapy App 20200246338 - Kind Code	2020-08-06
Combination therapy Grant 10,548,894 - Caponigro , et al. Fe	2020-02-04
Therapeutic Uses Of A C-raf Inhibitor App 20190358236 - CAPONIGRO; Giordano ; et al.	2019-11-28
Combination Therapy App 20180221370 - Caponigro; Giordano ; et al.	2018-08-09
Combination therapy Grant 9,913,844 - Caponigro , et al. March 13, 2	2018-03-13
Pharmaceutical combinations of a CDK4/6 inhibitor and a B-RAF inhibitor Grant 9,700,557 - Caponigro , et al. July 11, 2	2017-07-11
Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-.alpha. inhibitor Grant 9,474,754 - Caponigro , et al. October 25, 2	2016-10-25
Combination Therapy App 20160296520 - Caponigro; Giordano ; et al.	2016-10-13
Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway Grant 9,241,939 - Garcia-Echeverria , et al. January 26, 2	2016-01-26
Pharmaceutical Combinations Comprising a B-RAF Inhibitor, and EGFR Inhibitor and Optionally a PI3K-Alpha Inhibitor App 20150265616 - Caponigro; Giordano ; et al.	2015-09-24
Pharmaceutical Combinations of a CDK4/6 Inhibitor and a B-RAF Inhibitor App 20150164897 - Caponigro; Giordano ; et al.	2015-06-18
Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway App 20150105417 - Garcia-Echeverria; Carlos ; et al.	2015-04-16
Method of Treating a Proliferative Disease App 20140275136 - Stuart; Darrin ; et al.	2014-09-18
Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway App 20140057904 - Garcia-Echeverria; Carlos ; et al.	2014-02-27
Substituted benzimidazoles and methods of their use Grant 8,592,459 - Aikawa , et al. November 26, 2	2013-11-26
Substituted Benzimidazoles for the Treatment of Astrocytomas App 20110281917 - Stuart; Darrin	2011-11-17
Combination Of (a) A Phosphoinositide 3-kinase Inhibitor And (b) A Modulator Of Ras/raf/mek Pathway App 20110105521 - Garcia-Echeverria; Carlos ; et al.	2011-05-05
Substituted Benzimidazoles For Neurofibromatosis App 20110092546 - Stuart; Darrin	2011-04-21
Substituted Benzimidazoles And Methods Of Their Use App 20100234394 - Aikawa; Mina E. ; et al.	2010-09-16
Substituted benzimidazoles and methods of their use Grant 7,732,465 - Aikawa , et al. June 8, 2	2010-06-08
Biomarkers Of Target Modulation, Efficacy, Diagnosis And/or Prognosis For Raf Inhibitors App 20100004253 - Aziz; Natasha ; et al.	2010-01-07
Substituted benzimidazoles and methods of their use App 20090170904 - Aikawa; Mina E. ; et al.	2009-07-02
Substituted benzimidazoles and methods of their use Grant 7,482,367 - Aikawa , et al. January 27, 2	2009-01-27
Substituted benzimidazoles and methods of their use App 20070161680 - Alkawa; Mina E. ; et al.	2007-07-12

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.